Skip to main content

Table 6 Adverse events in 69 patients. 29 on Alirocumab 75 mg every 2 weeks, and Alirocumab 150 mg (n = 18) or Evolocumab 140 mg (n = 22) every 2 weeks (ALI-EVO)

From: Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study

 

All treatment groups (n = 69)

Alirocumab 75 mg every 2 weeks (n = 29)

ALI-EVO (n = 40)

Mean ± SD, median follow-up length

Mean ± SD, median follow-up length

Mean ± SD, median follow-up length

42 ± 14, 40 weeks

49 ± 13, 49 weeks

37 ± 12, 33 weeks

Flu-like symptoms

10 (14%)

1 (3%)

9 (23%)

Respiratory tract infection /symptoms

2 (3%)

1 (3%)

1 (3%)

Inject site reaction

1 (1%)

1 (3%)

 

Fatigue

2 (3%)

2 (7%)

 

Headache

2 (3%)

 

2 (5%)

Urticaria /itchiness

2 (3%)

1 (3%)

1 (3%)

G.I. symptom

2 (3%)

 

2 (5%)

Weight gain

2 (3%)

1 (3%)

1 (3%)

Hair loss

1 (1%)

 

1 (3%)

Any adverse events

24 (35%)

7 (24%)

17 (43%)

  1. Compare adverse events (any events) in the 2 treatment groups, χ2 = 2.50, p = .11
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X